We are interested in studying whether and how medical problems other than primary cancer before hematopoietic cell transplantation would impact the profiles of quality of life and toxicities post-transplantation for patients with blood cancers. We want to see if by assessing comorbidities (such as diabetes) early on, we can identify those patients who will have more toxicities or limitations in their quality of life after transplant. The generated information could set the stage for future intervention studies aiming to improve quality of life for patients with blood cancers after transplantation.

Inclusion Criteria:

• Allogeneic HCT candidates who are >18 years of age
• Able to speak and read English
• Able to provide informed consent
• Access to a telephone for study-related communications
• Diagnosed with a hematological malignant disease
• Willing to complete survey packets at 5 time-points, spanning two years

Exclusion Criteria:

• HCT candidates who are 18 years or younger at the time of study enrollment
• HCT candidates who cannot read, write, or speak English
• Patients with diagnoses of non-malignant diseases, or solid tumors are primary disease

Patients diagnosed with hematological malignancies who are being treated with allogeneic hematopoietic cell transplantation (HCT) at the Seattle Cancer Care Alliance.